Article
The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
European journal of haematology - 1 Apr 2017
Fathi Amir T, Chen Yi-Bin
Abstract excerpt
FLT3 mutations are present in about one-third of patients with acute myeloid leukemia (AML). Several FLT3 inhibitors have been used in clinical trials, and these include midostaurin, sorafenib, quizartinib, crenolanib, and gilteritinib. Monotherapy with early tyrosine kinase inhibitors (TKIs) did not have much success; however, later generation agents have shown more promising results. Combination with...
Topics
- Antineoplastic Agents
- Clinical Trials as Topic
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- fms-Like Tyrosine Kinase 3